Neural Plasticity
Volume 2016 (2016), Article ID 9364091, 10 pages
http://dx.doi.org/10.1155/2016/9364091
Review Article
The Endocannabinoid System as a Therapeutic Target in Glaucoma
1Department of Pharmacology, Dalhousie University, Halifax, NS, Canada B3H 4R2
2Department of Medical Neuroscience, Dalhousie University, Halifax, NS, Canada B3H 4R2
3Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada B3H 4R2
Received 10 July 2015; Accepted 10 November 2015
Academic Editor: Maurice Ptito
Copyright © 2016 Elizabeth A. Cairns et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Linked References
- S. Yazulla, “Endocannabinoids in the retina: from marijuana to neuroprotection,” Progress in Retinal and Eye Research, vol. 27, no. 5, pp. 501–526, 2008. View at Publisher · View at Google Scholar · View at Scopus
- K. Green, “Marihuana in ophthalmology: past, present and future,” Annals of Ophthalmology, vol. 11, no. 2, pp. 203–205, 1979. View at Google Scholar · View at Scopus
- C. Nucci, M. Bari, A. Spanò et al., “Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection,” Progress in Brain Research, vol. 173, pp. 451–464, 2008. View at Publisher · View at Google Scholar · View at Scopus
- T. Järvinen, D. W. Pate, and K. Laine, “Cannabinoids in the treatment of glaucoma,” Pharmacology & Therapeutics, vol. 95, no. 2, pp. 203–220, 2002. View at Publisher · View at Google Scholar · View at Scopus
- J. Chen, I. Matias, T. Dinh et al., “Finding of endocannabinoids in human eye tissues: implications for glaucoma,” Biochemical and Biophysical Research Communications, vol. 330, no. 4, pp. 1062–1067, 2005. View at Publisher · View at Google Scholar · View at Scopus
- A. J. Lee and I. Goldberg, “Emerging drugs for ocular hypertension,” Expert Opinion on Emerging Drugs, vol. 16, no. 1, pp. 137–161, 2011. View at Publisher · View at Google Scholar · View at Scopus
- A. King, A. Azuara-Blanco, and A. Tuulonen, “Glaucoma,” British Medical Journal, vol. 346, Article ID f3518, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
- H. A. Quigley, “Glaucoma,” The Lancet, vol. 377, no. 9774, pp. 1367–1377, 2011. View at Publisher · View at Google Scholar · View at Scopus
- A. Heijl, M. C. Leske, B. Bengtsson, L. Hyman, B. Bengtsson, and M. Hussein, “Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial,” Archives of Ophthalmology, vol. 120, no. 10, pp. 1268–1279, 2002. View at Publisher · View at Google Scholar · View at Scopus
- I. Matias, J. W. Wang, A. S. Moriello, A. Nieves, D. F. Woodward, and V. Di Marzo, “Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 75, no. 6, pp. 413–418, 2006. View at Publisher · View at Google Scholar · View at Scopus
- A. Porcella, P. Casellas, G. L. Gessa, and L. Pani, “Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana,” Molecular Brain Research, vol. 58, no. 1-2, pp. 240–245, 1998. View at Publisher · View at Google Scholar · View at Scopus
- T. Bisogno, I. Delton-Vandenbroucke, A. Milone, M. Lagarde, and V. Di Marzo, “Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina,” Archives of Biochemistry and Biophysics, vol. 370, no. 2, pp. 300–307, 1999. View at Publisher · View at Google Scholar · View at Scopus
- A. J. Straiker, G. Maguire, K. Mackie, and J. Lindsey, “Localization of cannabinoid CB1 receptors in the human anterior eye and retina,” Investigative Ophthalmology & Visual Science, vol. 40, no. 10, pp. 2442–2448, 1999. View at Google Scholar · View at Scopus
- A. Straiker, N. Stella, D. Piomelli, K. Mackie, H. J. Karten, and G. Maguire, “Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 25, pp. 14565–14570, 1999. View at Publisher · View at Google Scholar · View at Scopus
- S. Yazulla, K. M. Studholme, H. H. McIntosh, and D. G. Deutsch, “Immunocytochemical localization of cannabinoid CB1 receptor and fatty acid amide hydrolase in rat retina,” The Journal of Comparative Neurology, vol. 415, no. 1, pp. 80–90, 1999. View at Publisher · View at Google Scholar · View at Scopus
- Q. Lu, A. Straiker, Q. Lu, and G. Maguire, “Expression of CB2 cannabinoid receptor mRNA in adult rat retina,” Visual Neuroscience, vol. 17, no. 1, pp. 91–95, 2000. View at Publisher · View at Google Scholar · View at Scopus
- A. Porcella, C. Maxia, G. L. Gessa, and L. Pani, “The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein,” The European Journal of Neuroscience, vol. 12, no. 3, pp. 1123–1127, 2000. View at Publisher · View at Google Scholar · View at Scopus
- W. D. Stamer, S. F. Golightly, Y. Hosohata et al., “Cannabinoid CB1 receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues,” European Journal of Pharmacology, vol. 431, no. 3, pp. 277–286, 2001. View at Publisher · View at Google Scholar · View at Scopus
- E. M. López, P. Tagliaferro, E. S. Onaivi, and J. J. López-Costa, “Distribution of CB2 cannabinoid receptor in adult rat retina,” Synapse, vol. 65, no. 5, pp. 388–392, 2011. View at Publisher · View at Google Scholar · View at Scopus
- B. Cécyre, N. Zabouri, F. Huppé-Gourgues, J.-F. Bouchard, and C. Casanova, “Roles of cannabinoid receptors type 1 and 2 on the retinal function of adult mice,” Investigative Ophthalmology and Visual Science, vol. 54, no. 13, pp. 8079–8090, 2013. View at Publisher · View at Google Scholar · View at Scopus
- J. Bouskila, P. Javadi, C. Casanova, M. Ptito, and J.-F. Bouchard, “Müller cells express the cannabinoid CB2 receptor in the vervet monkey retina,” The Journal of Comparative Neurology, vol. 521, no. 11, pp. 2399–2415, 2013. View at Publisher · View at Google Scholar · View at Scopus
- G. Krishnan and N. Chatterjee, “Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation,” Glia, vol. 60, no. 11, pp. 1629–1645, 2012. View at Publisher · View at Google Scholar · View at Scopus
- L. Zhong, L. Geng, Y. Njie, W. Feng, and Z.-H. Song, “CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility,” Investigative Ophthalmology & Visual Science, vol. 46, no. 6, pp. 1988–1992, 2005. View at Publisher · View at Google Scholar · View at Scopus
- R. M. Sappington, T. Sidorova, D. J. Long, and D. J. Calkins, “TRPV1: contribution to retinal ganglion cell apoptosis and increased intracellular Ca2+ with exposure to hydrostatic pressure,” Investigative Ophthalmology & Visual Science, vol. 50, no. 2, pp. 717–728, 2009. View at Publisher · View at Google Scholar · View at Scopus
- M. Kohno, H. Hasegawa, A. Inoue et al., “Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18,” Biochemical and Biophysical Research Communications, vol. 347, no. 3, pp. 827–832, 2006. View at Publisher · View at Google Scholar · View at Scopus
- M. D. Caldwell, S. S.-J. Hu, S. Viswanathan, H. Bradshaw, M. E. M. Kelly, and A. Straiker, “A GPR18-based signalling system regulates IOP in murine eye,” British Journal of Pharmacology, vol. 169, no. 4, pp. 834–843, 2013. View at Publisher · View at Google Scholar · View at Scopus
- J. Macintyre, A. Dong, A. Straiker et al., “Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature,” European Journal of Pharmacology, vol. 735, no. 1, pp. 105–114, 2014. View at Publisher · View at Google Scholar · View at Scopus
- A. Kumar, Z. Qiao, P. Kumar, and Z.-H. Song, “Effects of palmitoylethanolamide on aqueous humor outflow,” Investigative Ophthalmology & Visual Science, vol. 53, no. 8, pp. 4416–4425, 2012. View at Publisher · View at Google Scholar · View at Scopus
- J. Bouskila, P. Javadi, C. Casanova, M. Ptito, and J.-F. Bouchard, “Rod photoreceptors express GPR55 in the adult vervet monkey retina,” PLoS ONE, vol. 8, no. 11, Article ID e81080, 2013. View at Publisher · View at Google Scholar · View at Scopus
- V. Di Marzo, “Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight,” Nature Neuroscience, vol. 14, no. 1, pp. 9–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
- D. Piomelli, “More surprises lying ahead. The endocannabinoids keep us guessing,” Neuropharmacology B, vol. 76, pp. 228–234, 2014. View at Publisher · View at Google Scholar · View at Scopus
- S. S.-J. Hu, A. Arnold, J. M. Hutchens et al., “Architecture of cannabinoid signaling in mouse retina,” The Journal of Comparative Neurology, vol. 518, no. 18, pp. 3848–3866, 2010. View at Publisher · View at Google Scholar · View at Scopus
- K. Tsuboi, Y.-X. Sun, Y. Okamoto, N. Araki, T. Tonai, and N. Ueda, “Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase,” The Journal of Biological Chemistry, vol. 280, no. 12, pp. 11082–11092, 2005. View at Publisher · View at Google Scholar · View at Scopus
- M. Alhouayek, J. Masquelier, and G. G. Muccioli, “Controlling 2-arachidonoylglycerol metabolism as an anti-inflammatory strategy,” Drug Discovery Today, vol. 19, no. 3, pp. 295–304, 2014. View at Publisher · View at Google Scholar · View at Scopus
- J. L. Blankman, G. M. Simon, and B. F. Cravatt, “A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol,” Chemistry & Biology, vol. 14, no. 12, pp. 1347–1356, 2007. View at Publisher · View at Google Scholar · View at Scopus
- D. F. Woodward, R. L. Jones, and S. Narumiya, “International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress,” Pharmacological Reviews, vol. 63, no. 3, pp. 471–538, 2011. View at Publisher · View at Google Scholar · View at Scopus
- M. Alhouayek and G. G. Muccioli, “COX-2-derived endocannabinoid metabolites as novel inflammatory mediators,” Trends in Pharmacological Sciences, vol. 35, no. 6, pp. 284–292, 2014. View at Publisher · View at Google Scholar · View at Scopus
- C. A. Rouzer and L. J. Marnett, “Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways,” Chemical Reviews, vol. 111, no. 10, pp. 5899–5921, 2011. View at Publisher · View at Google Scholar · View at Scopus
- K. R. Kozak, S. W. Rowlinson, and L. J. Marnett, “Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2,” The Journal of Biological Chemistry, vol. 275, no. 43, pp. 33744–33749, 2000. View at Publisher · View at Google Scholar · View at Scopus
- C. Maihöfner, U. Schlötzer-Schrehardt, H. Gühring et al., “Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes,” Investigative Ophthalmology & Visual Science, vol. 42, no. 11, pp. 2616–2624, 2001. View at Google Scholar · View at Scopus
- Y. F. Njie, Z. Qiao, Z. Xiao, W. Wang, and Z.-H. Song, “N-arachidonylethanolamide-induced increase in aqueous humor outflow facility,” Investigative Ophthalmology & Visual Science, vol. 49, no. 10, pp. 4528–4534, 2008. View at Publisher · View at Google Scholar · View at Scopus
- V. Di Marzo and S. Petrosino, “Endocannabinoids and the regulation of their levels in health and disease,” Current Opinion in Lipidology, vol. 18, no. 2, pp. 129–140, 2007. View at Publisher · View at Google Scholar · View at Scopus
- S. Giacoppo, G. Molino, M. Galuppo, and P. B. E. Mazzon, “Cannabinoids: new promising agents in the treatment of neurological diseases,” Molecules, vol. 19, no. 11, pp. 18781–18816, 2014. View at Publisher · View at Google Scholar · View at Scopus
- C. Nucci, V. Gasperi, R. Tartaglione et al., “Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats,” Investigative Ophthalmology & Visual Science, vol. 48, no. 7, pp. 2997–3004, 2007. View at Publisher · View at Google Scholar · View at Scopus
- W.-K. Ju, K.-Y. Kim, and A. H. Neufeld, “Increased activity of cyclooxygenase-2 signals early neurodegenerative events in the rat retina following transient ischemia,” Experimental Eye Research, vol. 77, no. 2, pp. 137–145, 2003. View at Publisher · View at Google Scholar · View at Scopus
- F. Carta, C. T. Supuran, and A. Scozzafava, “Novel therapies for glaucoma: a patent review 2007–2011,” Expert Opinion on Therapeutic Patents, vol. 22, no. 1, pp. 79–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
- P. L. Kaufman and C. A. Rasmussen, “Advances in glaucoma treatment and management: outflow drugs,” Investigative Ophthalmology & Visual Science, vol. 53, no. 5, pp. 2495–2500, 2012. View at Publisher · View at Google Scholar · View at Scopus
- K. Zhang, L. Zhang, and R. N. Weinreb, “Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma,” Nature Reviews Drug Discovery, vol. 11, no. 7, pp. 541–559, 2012. View at Publisher · View at Google Scholar · View at Scopus
- A. Porcella, C. Maxia, G. L. Gessa, and L. Pani, “The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies,” The European Journal of Neuroscience, vol. 13, no. 2, pp. 409–412, 2001. View at Publisher · View at Google Scholar · View at Scopus
- I. Tomida, A. Azuara-Blanco, H. House, M. Flint, R. G. Pertwee, and P. J. Robson, “Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study,” Journal of Glaucoma, vol. 15, no. 5, pp. 349–353, 2006. View at Publisher · View at Google Scholar
- P. Robson, “Therapeutic aspects of cannabis and cannabinoids,” The British Journal of Psychiatry, vol. 178, pp. 107–115, 2001. View at Publisher · View at Google Scholar · View at Scopus
- J. C. Merritt, D. D. Perry, D. N. Russell, and B. F. Jones, “Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma.,” Journal of Clinical Pharmacology, vol. 21, no. 8-9, supplement, pp. 467S–471S, 1981. View at Google Scholar · View at Scopus
- J. C. Merritt, W. J. Crawford, P. C. Alexander, A. L. Anduze, and S. S. Gelbart, “Effect of marihuana on intraocular and blood pressure in glaucoma,” Ophthalmology, vol. 87, no. 3, pp. 222–228, 1980. View at Publisher · View at Google Scholar · View at Scopus
- F. Y. Chien, R.-F. Wang, T. W. Mittag, and S. M. Podos, “Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys,” Archives of Ophthalmology, vol. 121, no. 1, pp. 87–90, 2003. View at Publisher · View at Google Scholar · View at Scopus
- Y. F. Njie, A. Kumar, Z. Qiao, L. Zhong, and Z.-H. Song, “Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility,” Investigative Ophthalmology & Visual Science, vol. 47, no. 5, pp. 1999–2005, 2006. View at Publisher · View at Google Scholar · View at Scopus
- Z.-H. Song and C.-A. Slowey, “Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2,” The Journal of Pharmacology and Experimental Therapeutics, vol. 292, no. 1, pp. 136–139, 2000. View at Google Scholar · View at Scopus
- B. D. Hudson, M. Beazley, A.-M. Szczesniak, A. Straiker, and M. E. M. Kelly, “Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists,” The Journal of Pharmacology and Experimental Therapeutics, vol. 339, no. 3, pp. 757–767, 2011. View at Publisher · View at Google Scholar · View at Scopus
- A.-M. Szczesniak, Y. Maor, H. Robertson, O. Hung, and M. E. M. Kelly, “Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure,” Journal of Ocular Pharmacology and Therapeutics, vol. 27, no. 5, pp. 427–435, 2011. View at Publisher · View at Google Scholar · View at Scopus
- M. M. Civan, “Formation of the aqueous humor: transport components and their integration,” Current Topics in Membranes, vol. 62, pp. 1–45, 2008. View at Google Scholar
- M. P. Fautsch and D. H. Johnson, “Aqueous humor outflow: what do we know? Where will it lead us?” Investigative Ophthalmology & Visual Science, vol. 47, no. 10, pp. 4181–4187, 2006. View at Publisher · View at Google Scholar · View at Scopus
- Y. F. Njie, F. He, Z. Qiao, and Z.-H. Song, “Aqueous humor outflow effects of 2-arachidonylglycerol,” Experimental Eye Research, vol. 87, no. 2, pp. 106–114, 2008. View at Publisher · View at Google Scholar · View at Scopus
- Y. Liang, D. F. Woodward, V. M. Guzman et al., “Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes,” British Journal of Pharmacology, vol. 154, no. 5, pp. 1079–1093, 2008. View at Publisher · View at Google Scholar · View at Scopus
- S. D. Smid, “Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: a closer look at the agonist properties of bimatoprost and the prostamides,” Clinical Ophthalmology, vol. 3, no. 1, pp. 663–670, 2009. View at Google Scholar · View at Scopus
- D. McHugh, S. S. J. Hu, N. Rimmerman et al., “N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor,” BMC Neuroscience, vol. 11, article 44, 2010. View at Publisher · View at Google Scholar · View at Scopus
- E. R. Tamm, L. Schmetterer, and F. Grehn, “Status and perspectives of neuroprotective therapies in glaucoma: the European Glaucoma Society White Paper,” Cell and Tissue Research, vol. 353, no. 2, pp. 347–354, 2013. View at Publisher · View at Google Scholar · View at Scopus
- J. Qu, D. Wang, and C. L. Grosskreutz, “Mechanisms of retinal ganglion cell injury and defense in glaucoma,” Experimental Eye Research, vol. 91, no. 1, pp. 48–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
- M. R. Hara and S. H. Snyder, “Cell signaling and neuronal death,” Annual Review of Pharmacology and Toxicology, vol. 47, pp. 117–141, 2007. View at Publisher · View at Google Scholar · View at Scopus
- J. Crandall, S. Matragoon, Y. M. Khalifa et al., “Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma,” Ophthalmic Research, vol. 39, no. 2, pp. 69–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
- A. B. El-Remessy, I. E. Khalil, S. Matragoon et al., “Neuroprotective effect of (–)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite,” American Journal of Pathology, vol. 163, no. 5, pp. 1997–2008, 2003. View at Publisher · View at Google Scholar · View at Scopus
- S. Pinar-Sueiro, J. Á. Zorrilla Hurtado, P. Veiga-Crespo, S. C. Sharma, and E. Vecino, “Neuroprotective effects of topical CB1 agonist WIN 55212-2 on retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat,” Experimental Eye Research, vol. 110, pp. 55–58, 2013. View at Publisher · View at Google Scholar · View at Scopus
- J. E. Slusar, E. A. Cairns, A.-M. Szczesniak, H. B. Bradshaw, A. Di Polo, and M. E. M. Kelly, “The fatty acid amide hydrolase inhibitor, URB597, promotes retinal ganglion cell neuroprotection in a rat model of optic nerve axotomy,” Neuropharmacology C, vol. 72, pp. 116–125, 2013. View at Publisher · View at Google Scholar · View at Scopus
- Y. Sakai, T. Tanaka, M. Seki et al., “Cyclooxygenase-2 plays a critical role in retinal ganglion cell death after transient ischemia: real-time monitoring of RGC survival using Thy-1-EGFP transgenic mice,” Neuroscience Research, vol. 65, no. 4, pp. 319–325, 2009. View at Publisher · View at Google Scholar · View at Scopus
- A. Mori, T. Ishii, T. Kuroki et al., “The prostanoid EP2 receptor agonist ONO-AE1-259-01 protects against glutamate-induced neurotoxicity in rat retina,” European Journal of Pharmacology, vol. 616, no. 1–3, pp. 64–67, 2009. View at Publisher · View at Google Scholar · View at Scopus
- N. N. Osborne, G.-Y. Li, D. Ji et al., “Expression of prostaglandin PGE2 receptors under conditions of aging and stress and the protective effect of the EP2 agonist butaprost on retinal ischemia,” Investigative Ophthalmology & Visual Science, vol. 50, no. 7, pp. 3238–3248, 2009. View at Publisher · View at Google Scholar · View at Scopus
- J. Y. Xu and C. Chen, “Endocannabinoids in synaptic plasticity and neuroprotection,” The Neuroscientist, vol. 21, no. 2, pp. 152–168, 2015. View at Publisher · View at Google Scholar
- M. Roh, Y. Zhang, Y. Murakami et al., “Etanercept, a widely used inhibitor of tumor necrosis factor-α (TNF-α), prevents retinal ganglion cell loss in a rat model of glaucoma,” PLoS ONE, vol. 7, no. 7, Article ID e40065, 2012. View at Publisher · View at Google Scholar · View at Scopus
- R. Vohra, J. C. Tsai, and M. Kolko, “The role of inflammation in the pathogenesis of glaucoma,” Survey of Ophthalmology, vol. 58, no. 4, pp. 311–320, 2013. View at Publisher · View at Google Scholar · View at Scopus
- X. Yang, C. Luo, J. Cai et al., “Neurodegenerative and inflammatory pathway components linked to TNF-alpha/TNFR1 signaling in the glaucomatous human retina,” Investigative Ophthalmology & Visual Science, vol. 52, no. 11, pp. 8442–8454, 2011. View at Publisher · View at Google Scholar · View at Scopus
- J. Zhang and C. Chen, “Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation,” The Journal of Biological Chemistry, vol. 283, no. 33, pp. 22601–22611, 2008. View at Publisher · View at Google Scholar · View at Scopus
- F. Drago, S. Valzelli, I. Emmi, A. Marino, C. C. Scalia, and V. Marino, “Latanoprost exerts neuroprotective activity in vitro and in vivo,” Experimental Eye Research, vol. 72, no. 4, pp. 479–486, 2001. View at Publisher · View at Google Scholar · View at Scopus
- W. M. Jay and K. Green, “Multiple-drop study of topically applied 1% delta 9-tetrahydrocannabinol in human eyes,” Archives of Ophthalmology, vol. 101, no. 4, pp. 591–593, 1983. View at Publisher · View at Google Scholar · View at Scopus
- N. Plange, K. O. Arend, M. Kaup et al., “Dronabinol and retinal hemodynamics in humans,” American Journal of Ophthalmology, vol. 143, no. 1, pp. 173–174, 2007. View at Publisher · View at Google Scholar · View at Scopus
- C. Gagliano, E. Ortisi, L. Pulvirenti et al., “Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial,” Investigative Ophthalmology and Visual Science, vol. 52, no. 9, pp. 6096–6100, 2011. View at Publisher · View at Google Scholar · View at Scopus
- A. Hosseini, F. A. Lattanzio, P. B. Williams, D. Tibbs, S. S. Samudre, and R. C. Allen, “Chronic topical administration of WIN-55-212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects,” Experimental Eye Research, vol. 82, no. 5, pp. 753–759, 2006. View at Publisher · View at Google Scholar · View at Scopus
- D. Fernández-Suárez, M. Celorrio, J. I. Riezu-Boj et al., “The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model,” Neurobiology of Aging, vol. 35, no. 11, pp. 2603–2616, 2014. View at Publisher · View at Google Scholar · View at Scopus
- S. Ghosh, L. E. Wise, Y. Chen et al., “The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model,” Life Sciences, vol. 92, no. 8-9, pp. 498–505, 2013. View at Publisher · View at Google Scholar · View at Scopus
- P. S. Katz, J. K. Sulzer, R. A. Impastato, S. X. Teng, E. K. Rogers, and P. E. Molina, “Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injur,” Journal of Neurotrauma, vol. 32, no. 5, pp. 297–306, 2015. View at Publisher · View at Google Scholar
- D. Wootten, A. Christopoulos, and P. M. Sexton, “Emerging paradigms in GPCR allostery: implications for drug discovery,” Nature Reviews Drug Discovery, vol. 12, no. 8, pp. 630–644, 2013. View at Publisher · View at Google Scholar · View at Scopus
- M. R. Price, G. L. Baillie, A. Thomas et al., “Allosteric modulation of the cannabinoid CB1 receptor,” Molecular Pharmacology, vol. 68, no. 5, pp. 1484–1495, 2005. View at Publisher · View at Google Scholar · View at Scopus
- R. G. Pertwee, “The pharmacology of cannabinoid receptors and their ligands: an overview,” International Journal of Obesity, vol. 30, supplement 1, pp. S13–S18, 2006. View at Publisher · View at Google Scholar · View at Scopus
- R. A. Ross, “Tuning the endocannabinoid system: allosteric modulators of the CB1 receptor,” British Journal of Pharmacology, vol. 152, no. 5, pp. 565–566, 2007. View at Publisher · View at Google Scholar · View at Scopus
- F. A. Pamplona, J. Ferreira, O. M. de Lima Jr. et al., “Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 51, pp. 21134–21139, 2012. View at Publisher · View at Google Scholar · View at Scopus
- G. L. Baillie, J. G. Horswill, S. Anavi-Goffer et al., “CB1 receptor allosteric modulators display both agonist and signaling pathway specificity,” Molecular Pharmacology, vol. 83, no. 2, pp. 322–338, 2013. View at Publisher · View at Google Scholar · View at Scopus
- P. Riordan-Eva, “Anatomy & embryology of the eye,” in Vaughan & Asbury's General Ophthalmology, P. Riordan-Eva and E. T. Cunningham, Eds., The McGraw-Hill Companies, New York, NY, USA, 18th edition, 2011. View at Google Scholar